Novartis (VTX:NOVN) received a CHF 83 target price from investment analysts at HSBC in a research report issued to clients and investors on Thursday, Borsen Zeitung reports. The brokerage currently has a “neutral” rating on the stock.
A number of other analysts have also recently issued reports on the company. Kepler Capital Markets set a CHF 86 target price on Novartis and gave the company a “buy” rating in a research report on Tuesday, April 16th. Barclays set a CHF 75 target price on Novartis and gave the company a “sell” rating in a research report on Wednesday, January 16th. JPMorgan Chase & Co. set a CHF 85 target price on Novartis and gave the company a “sell” rating in a research report on Tuesday, April 9th. Goldman Sachs Group set a CHF 110 target price on Novartis and gave the company a “buy” rating in a research report on Monday, March 25th. Finally, Deutsche Bank set a CHF 85 target price on Novartis and gave the company a “neutral” rating in a research report on Thursday. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of CHF 88.71.
Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.
Novartis Company Profile
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
See Also: Earnings Reports
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.